Article Versions Notes

Rzewińska A, Szlęk J, Dąbrowski D, Juszczyk E, Mróz K, Räikkönen H, Siven M, Wieczorek M, Dorożyński P. Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116. Pharmaceutics. 2024; 16(9):1157. https://doi.org/10.3390/pharmaceutics16091157

Rzewińska, Aleksandra, Jakub Szlęk, Damian Dąbrowski, Ewelina Juszczyk, Katarzyna Mróz, Heikki Räikkönen, Mia Siven, Maciej Wieczorek, and Przemysław Dorożyński. 2024. "Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116" Pharmaceutics 16, no. 9: 1157. https://doi.org/10.3390/pharmaceutics16091157

Rzewińska, A., Szlęk, J., Dąbrowski, D., Juszczyk, E., Mróz, K., Räikkönen, H., Siven, M., Wieczorek, M., & Dorożyński, P. (2024). Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116. Pharmaceutics, 16(9), 1157. https://doi.org/10.3390/pharmaceutics16091157